Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Total debt
Abivax SA Sponsored ADR's total debt at the end of fiscal 2025 was $2.1M, down 98.0% from $104.1M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.4M. Over the past ten years it has ranged from $2.1M (fiscal 2025) to $104.1M (fiscal 2024) — the current reading is the lowest in ten years. Abivax SA Sponsored ADR ranks 367th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $2.1M | (97.98%) |
| FY2024 | $104.1M | 73.40% |
| FY2023 | $60.0M | 45.49% |
| FY2022 | $41.3M | (32.11%) |
| FY2021 | $60.8M | 46.18% |
| FY2020 | $41.6M | 78.57% |
| FY2019 | $23.3M | 86.87% |
| FY2018 | $12.5M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $1.4M | (16.79%) |
| Mar 2026 | $1.7M | (19.35%) |
| Dec 2025 | $2.1M | (96.09%) |
| Sep 2025 | $53.6M | (44.13%) |
| 10 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $864.1M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| AXSM Axsome Therapeutics, Inc. compare | $127.3M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | $106.1M |
| CORT Corcept Therapeutics Incorporated compare | $5.0M |
| PRAX Praxis Precision Medicines, Inc. compare | $2.8M |
| ABVX Abivax SA Sponsored ADR | $1.4M |
| ORKA Oruka Therapeutics, Inc. compare | $301.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt